20
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Long-Term Growth Hormone Therapy in Mitochondrial Cytopathy

      case-report

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective: To describe in a 5-year-old Caucasian male with mitochondrial cytopathy, a biochemical growth hormone (GH) deficiency associated with normal GH biological activity as evaluated by Nb<sub>2</sub> cell bioassay and normal serum IGF-I and IGFBP3 values increasing slightly after GH administration. Method: Serum GH concentrations were measured with a commercial immunofluorometric assay and with a biological assay, which uses the Nb<sub>2</sub> cell line. Serum IGF-I and IGFBP3 concentrations were measured with RIA. Results: The GH-supplementary therapy was initially effective in terms of growth gain, but no therapeutic benefit was observed over a long period of time. Conclusion: In patients suffering from mitochondrial cytopathy, short stature seems to be attributed more to a disease-related inadequate protein substrate than to the non-classical GH deficiency.

          Related collections

          Most cited references2

          • Record: found
          • Abstract: not found
          • Article: not found

          Diabetes mellitus associated with a pathogenic point mutation in mitochondrial DNA

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Kearns-Sayre syndrome. A review of a multisystem disorder of children and young adults.

            The syndrome of a slowly progressive external ophthalmoplegia, pigment retinopathy, and disorder of cardiac conduction was described by Kearns and Sayre in 1958. In patients with this triad, other neurological deficits may occur with associated abnormalities of the electrocardiogram, electroencephalogram, audiogram, and an elevation of protein in cerebrospinal fluid. The onset of a potentially lethal cardiac dysrhythmia in a patient with this slowly progressive degeneration of the nervous system can be anticipated and prevented by the use of an artivicial cardiac pacemaker.
              Bookmark

              Author and article information

              Journal
              HRE
              Horm Res Paediatr
              10.1159/issn.1663-2818
              Hormone Research in Paediatrics
              S. Karger AG
              1663-2818
              1663-2826
              2004
              September 2004
              13 September 2004
              : 62
              : 2
              : 103-106
              Affiliations
              aDepartment of Pediatrics, University of Pavia, IRCCS San Matteo, and bDepartment of Child Neurology and Psychiatry ‘C. Mondino’ Foundation, University of Pavia, Pavia, Italy
              Article
              80451 Horm Res 2004;62:103–106
              10.1159/000080451
              15331853
              289c37f1-7cb5-49f0-be63-0ba0ad58b625
              © 2004 S. Karger AG, Basel

              Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

              History
              : 22 December 2003
              : 22 June 2004
              Page count
              Figures: 2, References: 17, Pages: 4
              Categories
              Case Report

              Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
              Growth hormone therapy,Growth hormone deficiency,Mitochondrial cytopathy

              Comments

              Comment on this article